Effects of SLCO1B1 on elimination and toxicities of high-dose methotrexate in pediatric acute lymphoblastic leukemia

Review Pharmacology & Pharmacy

PharmVar GeneFocus: SLCO1B1

Laura B. Ramsey et al.

Summary: PharmVar provides star allele nomenclature for the SLCO1B1 gene, which plays an important role in drug transport and metabolism. The standardized nomenclature has been adopted by CPIC and incorporated into guidelines.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2023)

Add to Collection

Article Medicine, Research & Experimental

Effect ofSLCO1B1Polymorphisms on High-Dose Methotrexate Clearance in Children and Young Adults With Leukemia and Lymphoblastic Lymphoma

Rachael R. Schulte et al.

Summary: High-dose methotrexate is a critical treatment component for hematologic malignancies in children and young adults. This study found that patient weight and SLCO1B1 genotype significantly influence MTX clearance variability, highlighting the importance of considering these factors in personalized dosing of high-dose MTX.

CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2021)

Add to Collection

Article Hematology

Risk factors for delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia and lymphoma

Takaaki Nakano et al.

Summary: Delayed elimination of high-dose methotrexate, used in patients with leukemia and lymphoma, was found to be associated with factors such as the first course of treatment, urine volume, total bilirubin level, eGFR, MTX dose, and urine volume on the day after treatment initiation.

INTERNATIONAL JOURNAL OF HEMATOLOGY (2021)

Add to Collection

Article Oncology

Genetic factors involved in delayed methotrexate elimination in children with acute lymphoblastic leukemia

Yu Cheng et al.

Summary: The study found that the genetic polymorphism SLCO1B1 rs2306283 is associated with delayed elimination of methotrexate and increased risk of toxicities such as oral mucositis, hepatotoxicity, and myelosuppression in children with acute lymphoblastic leukemia.

PEDIATRIC BLOOD & CANCER (2021)

Add to Collection

Article Pharmacology & Pharmacy

HLA-DRB1*16:02 is associated with PEG-asparaginase hypersensitivity

Shuguang Liu et al.

Summary: T-ALL and higher risk groups have a higher risk of PEG-asparaginase hypersensitivity. There is no association between NFATC2 rs6021191 and PEG-asparaginase hypersensitivity. The HLA-DRB1*16:02 variant is associated with PEG-asparaginase allergy.

PHARMACOGENOMICS (2021)

Add to Collection

Review Oncology

Systematic Review of Pharmacogenetic Factors That Influence High-Dose Methotrexate Pharmacokinetics in Pediatric Malignancies

Zachary L. Taylor et al.

Summary: High-dose methotrexate is commonly used in cancer treatment, but its variability in elimination can lead to serious adverse events. While many studies have looked into how genetic factors influence methotrexate elimination, conflicting results and lack of replication and validation have hindered progress. Despite identifying some genes affecting methotrexate clearance, more research is needed to confirm their effects and improve patient outcomes.

CANCERS (2021)

Add to Collection

Article Genetics & Heredity